MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

Chiara Perfumo; Stefano Parodi; Katia Mazzocco; Raffaella Defferrari; Alberto Inga; Giovanna Bianchi Scarrà; Paola Ghiorzo; Riccardo Haupt; Gian Paolo Tonini; Gilberto Fronza

doi:10.1002/pbc.22132

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

Chiara Perfumo, Stefano Parodi, Katia Mazzocco, Raffaella Defferrari, Alberto Inga, Giovanna Bianchi Scarrà, Paola Ghiorzo, Riccardo Haupt, Gian Paolo Tonini, Gilberto Fronza

Research output: Contribution to journal › Article

Abstract

Background. MDM2 is a major negative regulator of p53 function and is directly regulated by MYCN in neuroblastoma (NB) cells. MDM2 SNP309, a T-to-G substitution in the MDM2 promoter associated with higher gene expression compared to wild-type, may attenuate the p53 pathway in NB, in which p53 mutations are rare. We investigated its impact on NB development and survival in relation with major clinical and biological characteristics. Procedure. A consecutive cohort of 497 NB children, diagnosed in Italy between 1995 and 2005, and a healthy control population of 471 adults were genotyped for MDM2 SNP309. NB patients were followed up until June 30, 2008. Results. Patients and controls showed similar distribution of MDM2 SNP309 genotypes. In patients, the polymorphism was not associated with any characteristic at diagnosis. In localized stages no effect of the polymorphism on survival was evident. In stage 4 patients overall survival (OS), event free survival (EFS) and survival after relapse (SAR) were significantly poorer for TG/GG than for TT patients (P=0.008; P=0.013; P=0.046, respectively). In this group, such an effect was more evident in patients with MYCN amplification (OS: P

Original language	English
Pages (from-to)	576-583
Number of pages	8
Journal	Pediatric Blood and Cancer
Volume	53
Issue number	4
DOIs	https://doi.org/10.1002/pbc.22132
Publication status	Published - Oct 2009

Fingerprint

Keywords

MDM2
Neuroblastoma
Polymorphism
Progression
Survival

ASJC Scopus subject areas

Oncology
Pediatrics, Perinatology, and Child Health
Hematology
Medicine(all)

Cite this

Perfumo, C., Parodi, S., Mazzocco, K., Defferrari, R., Inga, A., Scarrà, G. B., Ghiorzo, P., Haupt, R., Tonini, G. P., & Fronza, G. (2009). MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatric Blood and Cancer, 53(4), 576-583. https://doi.org/10.1002/pbc.22132

MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. / Perfumo, Chiara; Parodi, Stefano; Mazzocco, Katia; Defferrari, Raffaella; Inga, Alberto; Scarrà, Giovanna Bianchi; Ghiorzo, Paola ; Haupt, Riccardo; Tonini, Gian Paolo; Fronza, Gilberto.

In: Pediatric Blood and Cancer, Vol. 53, No. 4, 10.2009, p. 576-583.

Research output: Contribution to journal › Article

@article{ecd6180ff56d4baa9f1bbcc54b10a871,

title = "MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma",

abstract = "Background. MDM2 is a major negative regulator of p53 function and is directly regulated by MYCN in neuroblastoma (NB) cells. MDM2 SNP309, a T-to-G substitution in the MDM2 promoter associated with higher gene expression compared to wild-type, may attenuate the p53 pathway in NB, in which p53 mutations are rare. We investigated its impact on NB development and survival in relation with major clinical and biological characteristics. Procedure. A consecutive cohort of 497 NB children, diagnosed in Italy between 1995 and 2005, and a healthy control population of 471 adults were genotyped for MDM2 SNP309. NB patients were followed up until June 30, 2008. Results. Patients and controls showed similar distribution of MDM2 SNP309 genotypes. In patients, the polymorphism was not associated with any characteristic at diagnosis. In localized stages no effect of the polymorphism on survival was evident. In stage 4 patients overall survival (OS), event free survival (EFS) and survival after relapse (SAR) were significantly poorer for TG/GG than for TT patients (P=0.008; P=0.013; P=0.046, respectively). In this group, such an effect was more evident in patients with MYCN amplification (OS: P",

keywords = "MDM2, Neuroblastoma, Polymorphism, Progression, Survival",

author = "Chiara Perfumo and Stefano Parodi and Katia Mazzocco and Raffaella Defferrari and Alberto Inga and Scarr{\`a}, {Giovanna Bianchi} and Paola Ghiorzo and Riccardo Haupt and Tonini, {Gian Paolo} and Gilberto Fronza",

year = "2009",

month = oct,

doi = "10.1002/pbc.22132",

language = "English",

volume = "53",

pages = "576--583",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "John Wiley and Sons Inc.",

number = "4",

}

TY - JOUR

T1 - MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma

AU - Perfumo, Chiara

AU - Parodi, Stefano

AU - Mazzocco, Katia

AU - Defferrari, Raffaella

AU - Inga, Alberto

AU - Scarrà, Giovanna Bianchi

AU - Ghiorzo, Paola

AU - Haupt, Riccardo

AU - Tonini, Gian Paolo

AU - Fronza, Gilberto

PY - 2009/10

Y1 - 2009/10

N2 - Background. MDM2 is a major negative regulator of p53 function and is directly regulated by MYCN in neuroblastoma (NB) cells. MDM2 SNP309, a T-to-G substitution in the MDM2 promoter associated with higher gene expression compared to wild-type, may attenuate the p53 pathway in NB, in which p53 mutations are rare. We investigated its impact on NB development and survival in relation with major clinical and biological characteristics. Procedure. A consecutive cohort of 497 NB children, diagnosed in Italy between 1995 and 2005, and a healthy control population of 471 adults were genotyped for MDM2 SNP309. NB patients were followed up until June 30, 2008. Results. Patients and controls showed similar distribution of MDM2 SNP309 genotypes. In patients, the polymorphism was not associated with any characteristic at diagnosis. In localized stages no effect of the polymorphism on survival was evident. In stage 4 patients overall survival (OS), event free survival (EFS) and survival after relapse (SAR) were significantly poorer for TG/GG than for TT patients (P=0.008; P=0.013; P=0.046, respectively). In this group, such an effect was more evident in patients with MYCN amplification (OS: P

AB - Background. MDM2 is a major negative regulator of p53 function and is directly regulated by MYCN in neuroblastoma (NB) cells. MDM2 SNP309, a T-to-G substitution in the MDM2 promoter associated with higher gene expression compared to wild-type, may attenuate the p53 pathway in NB, in which p53 mutations are rare. We investigated its impact on NB development and survival in relation with major clinical and biological characteristics. Procedure. A consecutive cohort of 497 NB children, diagnosed in Italy between 1995 and 2005, and a healthy control population of 471 adults were genotyped for MDM2 SNP309. NB patients were followed up until June 30, 2008. Results. Patients and controls showed similar distribution of MDM2 SNP309 genotypes. In patients, the polymorphism was not associated with any characteristic at diagnosis. In localized stages no effect of the polymorphism on survival was evident. In stage 4 patients overall survival (OS), event free survival (EFS) and survival after relapse (SAR) were significantly poorer for TG/GG than for TT patients (P=0.008; P=0.013; P=0.046, respectively). In this group, such an effect was more evident in patients with MYCN amplification (OS: P

KW - MDM2

KW - Neuroblastoma

KW - Polymorphism

KW - Progression

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=69849106415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69849106415&partnerID=8YFLogxK

U2 - 10.1002/pbc.22132

DO - 10.1002/pbc.22132

M3 - Article

C2 - 19526525

AN - SCOPUS:69849106415

VL - 53

SP - 576

EP - 583

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -

Access to Document

10.1002/pbc.22132